Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Comparator-controlled, Cross-over Intervention Study to Assess Renal Hemodynamics of Mono- and Combination Therapy With SGLT-2 Inhibitor Empagliflozin and RAS-inhibitor Losartan in Patients With Type 2 Diabetes Mellitus

NCT04238702 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT04238702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04238702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Comparator-controlled, Cross-over Intervention Study to Assess Renal Hemodynamics of Mono- and Combination Therapy With SGLT-2 Inhibitor Empagliflozin and RAS-inhibitor Losartan in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 4
Overall status
Completed
Start date
November 4, 2020
Completion date
September 27, 2021
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, diabetic kidney disease